Related Experiment Video
Updated: Jul 21, 2025

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
COVID-19 and HIV: Clinical Outcomes among Hospitalized Patients in the United States
Zohaa Faiz1, Mohammed A Quazi2, Neel Vahil3
1Department of Medicine, School of Medicine, Aga Khan University, Karachi 74000, Pakistan.
Insights
Patients with HIV and COVID-19 had similar mortality rates but higher rates of acute kidney injury (AKI) compared to those with COVID-19 alone. Further research is needed on factors influencing these outcomes in co-infected individuals.
Area of Science:
- Infectious Diseases
- Public Health
- Internal Medicine
Background:
- The co-occurrence of Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19) presents unique healthcare challenges.
- Individuals with HIV may be at increased risk for SARS-CoV-2 infection and adverse clinical outcomes.
- COVID-19 disproportionately affects marginalized populations, including African Americans and those with lower socioeconomic status.
Purpose of the Study:
- To compare in-hospital mortality and secondary outcomes between patients with both HIV and COVID-19 and those with COVID-19 alone.
- To identify specific complications and resource utilization differences in co-infected patients.
Main Methods:
- Retrospective analysis of the National Inpatient Sample (NIS) database.
- Comparison of patients diagnosed with both HIV and COVID-19 against a cohort with COVID-19 only.
- Primary outcome: in-hospital mortality. Secondary outcomes included intubation, vasopressor use, acute myocardial infarction, acute kidney injury (AKI), AKI requiring hemodialysis, venous thromboembolism, septic shock, cardiac arrest, length of stay, financial burden, and resource utilization.
Main Results:
- A total of 1,572,815 patients were analyzed (99.4% COVID-19 only, 0.56% HIV and COVID-19).
- No significant difference in in-hospital mortality was observed between the two groups (10.2% vs. 11.3%, p=0.35).
- Patients with both HIV and COVID-19 exhibited a significantly higher rate of AKI (33.6% vs. 28.6%, aOR: 1.26, p<0.001).
Conclusions:
- While mortality risk was similar, HIV and COVID-19 co-infection is associated with an increased incidence of acute kidney injury.
- Further prospective research is warranted to explore the impact of viral load, CD4 count, and antiretroviral therapy on outcomes in co-infected patients.
- Understanding these complex interactions is crucial for optimizing care for individuals living with HIV during the COVID-19 pandemic.
Abstract:
The concurrence of HIV and COVID-19 yields unique challenges and considerations for healthcare providers, patients living with HIV, and healthcare systems at-large. Persons living with HIV may face a higher risk of acquiring SARS-CoV-2 infection and experiencing worse clinical outcomes compared to those without. Notably, COVID-19 may have a disproportionate impact on historically disadvantaged populations, including African Americans and those stratified in a lower socio-economic status. Using the National Inpatient Sample (NIS) database, we compared patients with a diagnosis of both HIV and COVID-19 and those who exclusively had a diagnosis of COVID-19. The primary outcome was in-hospital mortality. Secondary outcomes were intubation rate and vasopressor use; acute MI, acute kidney injury (AKI); AKI requiring hemodialysis (HD); venous thromboembolism (VTE); septic shock and cardiac arrest; length of stay; financial burden on healthcare; and resource utilization. A total of 1,572,815 patients were included in this study; a COVID-19-positive sample that did not have HIV (n = 1,564,875, 99.4%) and another sample with HIV and COVID-19 (n = 7940, 0.56%). Patients with COVID-19 and HIV did not have a significant difference in mortality compared to COVID-19 alone (10.2% vs. 11.3%, respectively, p = 0.35); however, that patient cohort did have a significantly higher rate of AKI (33.6% vs. 28.6%, aOR: 1.26 [95% CI 1.13-1.41], p < 0.001). Given the complex interplay between HIV and COVID-19, more prospective studies investigating the factors such as the contribution of viral burden, CD4 cell count, and the details of patients' anti-retroviral therapeutic regimens should be pursued.
More Related Videos
13:50Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
Published on: June 11, 2011
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pneumonia III: Complications and Assessment
Sexually Transmitted Infections
Retrovirus Life Cycles
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...